Global Non-small Cell Lung Cancer Therapeutics Market Research Report 2019

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
• 1.4 Market by Type
  • 1.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Alimta
  • 1.4.3 Iressa
  • 1.4.4 Avastin
  • 1.4.5 Tarceva
  • 1.4.6 Zykadia
  • 1.4.7 Tagrisso
  • 1.4.8 Xalkori
  • 1.4.9 Cyramza
  • 1.4.10 Opdivo
  • 1.4.11 Alecensa
• 1.5 Market by Application
  • 1.5.1 Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital
  • 1.5.3 Clinic
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Non-small Cell Lung Cancer Therapeutics Market Perspective (2015-2026)
• 2.2 Global Non-small Cell Lung Cancer Therapeutics Growth Trends by Regions
  • 2.2.1 Non-small Cell Lung Cancer Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Non-small Cell Lung Cancer Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Non-small Cell Lung Cancer Therapeutics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Non-small Cell Lung Cancer Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Market Size
  • 3.1.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Non-small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio
  • 3.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Therapeutics Revenue in 2019
• 3.3 Non-small Cell Lung Cancer Therapeutics Key Players Head office and Area Served
• 3.4 Key Players Non-small Cell Lung Cancer Therapeutics Product Solution and Service
• 3.5 Date of Enter into Non-small Cell Lung Cancer Therapeutics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
• 5.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
• 6.2 Non-small Cell Lung Cancer Therapeutics Key Players in North America (2019-2020)
• 6.3 North America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
• 6.4 North America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
• 7.2 Non-small Cell Lung Cancer Therapeutics Key Players in Europe (2019-2020)
• 7.3 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
• 7.4 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

8 China

• 8.1 China Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
• 8.2 Non-small Cell Lung Cancer Therapeutics Key Players in China (2019-2020)
• 8.3 China Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
• 8.4 China Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
• 9.2 Non-small Cell Lung Cancer Therapeutics Key Players in Japan (2019-2020)
• 9.3 Japan Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
• 9.4 Japan Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
• 10.2 Non-small Cell Lung Cancer Therapeutics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

11 India

• 11.1 India Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
• 11.2 Non-small Cell Lung Cancer Therapeutics Key Players in India (2019-2020)
• 11.3 India Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
• 11.4 India Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
• 12.2 Non-small Cell Lung Cancer Therapeutics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
• 12.4 Central & South America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 GlaxoSmithKline
  • 13.1.1 GlaxoSmithKline Company Details
  • 13.1.2 GlaxoSmithKline Business Overview
  • 13.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Introduction
  • 13.1.4 GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020))
  • 13.1.5 GlaxoSmithKline Recent Development
• 13.2 Novartis
  • 13.2.1 Novartis Company Details
  • 13.2.2 Novartis Business Overview
  • 13.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Introduction
  • 13.2.4 Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
  • 13.2.5 Novartis Recent Development
• 13.3 AstraZeneca
  • 13.3.1 AstraZeneca Company Details
  • 13.3.2 AstraZeneca Business Overview
  • 13.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Introduction
  • 13.3.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
  • 13.3.5 AstraZeneca Recent Development
• 13.4 Roche
  • 13.4.1 Roche Company Details
  • 13.4.2 Roche Business Overview
  • 13.4.3 Roche Non-small Cell Lung Cancer Therapeutics Introduction
  • 13.4.4 Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
  • 13.4.5 Roche Recent Development
• 13.5 Bristol-Myers Squibb
  • 13.5.1 Bristol-Myers Squibb Company Details
  • 13.5.2 Bristol-Myers Squibb Business Overview
  • 13.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Introduction
  • 13.5.4 Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
  • 13.5.5 Bristol-Myers Squibb Recent Development
• 13.6 Pfizer
  • 13.6.1 Pfizer Company Details
  • 13.6.2 Pfizer Business Overview
  • 13.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Introduction
  • 13.6.4 Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
  • 13.6.5 Pfizer Recent Development
• 13.7 Eli Lilly
  • 13.7.1 Eli Lilly Company Details
  • 13.7.2 Eli Lilly Business Overview
  • 13.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Introduction
  • 13.7.4 Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
  • 13.7.5 Eli Lilly Recent Development
• 13.8 Sanofi
  • 13.8.1 Sanofi Company Details
  • 13.8.2 Sanofi Business Overview
  • 13.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Introduction
  • 13.8.4 Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
  • 13.8.5 Sanofi Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer